Beam Therapeutics (BEAM) Enterprise Value (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Enterprise Value data on file, last reported at -$1.2 billion in Q1 2026.

• On a quarterly basis, Enterprise Value rose 0.68% year-over-year to -$1.2 billion in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 0.68% increase from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 46.37% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.2 billion, up from -$1.2 billion in the prior quarter.
• Over the last five years, Enterprise Value for BEAM reached as high as -$850.7 million in Q4 2024 and fell as low as -$1.2 billion in Q4 2025.
• Historically, Enterprise Value has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2022.
• Across the five-year window, Enterprise Value tumbled 142.83% in 2022 and gained 28.5% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$1.1 billion in 2022, then fell by 10.36% to -$1.2 billion in 2023, then rose by 28.5% to -$850.7 million in 2024, then sank by 46.37% to -$1.2 billion in 2025, then rose by 2.69% to -$1.2 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$1.2 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.